Eli Lilly and Company announced positive topline results from its SURPASS-PEDS Phase 3 trial for Mounjaro (tirzepatide). The study, which evaluated the GIP/GLP-1 dual receptor agonist in children and adolescents with type 2 diabetes, demonstrated substantial and statistically significant improvements in blood sugar control and weight management, with a safety profile consistent with adult studies.
Eli Lilly’s once-weekly insulin, efsitora alfa, has shown promising results in Phase 3 clinical trials. The innovative treatment demonstrated A1C reductions comparable to daily basal insulins, with a consistent safety profile.
In addition, the research showed an 80% reduction in the hospitalization risk of cardiovascular disease in individuals with Type 1 diabetes who did not have a previous history of such illnesses.
In a Phase 3 trial, orforglipron, the first small molecule GLP-1, successfully reduced A1C by an average of 1.3% to 1.6% across dosages.
In addition to being the first to examine the safety and effectiveness of an automated insulin delivery (AID) system in conjunction with an Abbott FreeStyle Libre® 2 family sensor
The active ingredient in the diabetes and weight-loss medications Wegovy and Ozempic is semaglutide, a glucagon-like peptide receptor (GLP-1R) molecule that reduces appetite and aids in blood sugar regulation in type 2 diabetes.
The first study in the world, conducted recently at the University of Eastern Finland, demonstrates that even in those with a high hereditary risk, type [Read More…]
The drug is special, say the researchers, since it specifically targets the beta cells in the pancreas that produce insulin and is made to protect those cells against the immune system attacks.
Pancreatic beta cells (β-cells) are the only cells that can produce insulin, and a significant cause of diabetes is a reduction in these cells
A University of Alberta team has developed a new step to improve the process for creating insulin-producing pancreatic cells from a patient’s own stem cells, bringing the prospect of injection-free treatment closer for people with diabetes.
